Maria Prelipcean, MD
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1457326779
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 557 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations.
Across 557 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Abbott$853
- Dexcom, Inc.$801
- Boehringer Ingelheim$797
- plus $4K from 29 others
What the payments were for
- Food & beverage$9,89799%
- Education$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 71 | $1,226 |
| Novo Nordisk | 86 | $1,166 |
| Lilly USA, LLC | 68 | $1,007 |
| Abbott | 50 | $853 |
| Dexcom, Inc. | 38 | $801 |
| Boehringer Ingelheim | 52 | $797 |
| Medtronic(2 entities) | 15 | $619 |
| AstraZeneca | 31 | $529 |
| Corcept Therapeutics | 21 | $414 |
| Xeris Pharmaceuticals, Inc. | 19 | $377 |
| Amgen(2 entities) | 17 | $286 |
| Tandem Diabetes Care, Inc. | 12 | $241 |
| AbbVie | 13 | $240 |
| Sanofi-aventis U.S. LLC | 13 | $232 |
| IBSA Pharma Inc. | 9 | $195 |
| Insulet Corporation | 8 | $170 |
| Sequel Med Tech, LLC | 1 | $118 |
| Kowa Pharmaceuticals America, Inc. | 1 | $116 |
| Novartis | 5 | $98 |
| Neurocrine Biosciences, Inc. | 3 | $72 |
| BETA Bionics, Inc. | 3 | $67 |
| Kyowa Kirin, Inc. | 3 | $64 |
| Amarin Pharma, Inc. | 4 | $50 |
| Endogastric Solutions, Inc | 1 | $30 |
| Johnson & Johnson | 2 | $28 |
| Radius Health, Inc. | 2 | $25 |
| Rhythm Pharmaceuticals, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Merck | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Senseonics, Incorporated | 1 | $16 |
| Averitas Pharma Inc. | 1 | $16 |
| Companion Medical, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$402
- FreeStyle Libre$126
- TWIIST$118
- Livalo$116
How this compares
$9,972 in reported general payments places this provider in the 60th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 271 | $266,612 |
| MounjaroTirzepatide | 179 | $209,781 |
| JardianceEmpagliflozin | 117 | $127,070 |
| TrulicityDulaglutide | 68 | $84,717 |
| JanuviaSitagliptin Phosphate | 73 | $52,622 |
| HumalogInsulin Lispro | 118 | $29,655 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $27,727 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $23,969 |
| FarxigaDapagliflozin Propanediol | 14 | $23,683 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $22,404 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 197 | $20,908 |
| SynthroidLevothyroxine Sodium | 300 | $20,297 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $18,894 |
| Repatha SureclickEvolocumab | 31 | $17,236 |
| NovologInsulin Aspart | 43 | $17,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro | $1,007 | $334,702414 claims |
| Novo NordiskOzempic, Novolog, Rybelsus | $1,166 | $295,394329 claims |
| Boehringer IngelheimJardiance, Tradjenta | $797 | $133,387129 claims |
| MerckJanuvia | $17 | $52,62273 claims |
| AstraZenecaFarxiga | $529 | $23,68314 claims |
| AbbVieSynthroid | $240 | $20,297300 claims |
| IBSA Pharma Inc.Tirosint | $195 | $9,41547 claims |
| BayerKerendia | $1,226 | $9,06814 claims |
| Johnson & JohnsonInvokana | $28 | $6,41611 claims |
| Sanofi-aventis U.S. LLCLantus | $232 | $2,05219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Fernando OvalleBirmingham$15K
- Jennifer SohnBirmingham$14K
- Jorge PinoBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.